Journal
ACG CASE REPORTS JOURNAL
Volume 9, Issue 11, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/crj.0000000000000881
Keywords
-
Categories
Funding
- Chan Zuckerberg Biohub Physician Scientist Scholar Award
- NIH NIDDK LRP Award [L30 DK126220]
- Doris Duke Phy-sician Scientist Fellowship Award [2021091]
Ask authors/readers for more resources
This study presents the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with ulcerative colitis successfully treated with ustekinumab.
Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal manifestations of UC are unclear. Sweet syndrome, an acute febrile neutrophilic dermatosis, is a cutaneous manifestation of inflammatory bowel disease that parallels disease activity. In this study, we present the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with UC successfully treated with ustekinumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available